This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Hamada, A. Articles by Figg, W. D. PubMed PubMed Citation Articles by Hamada, A. Articles by Figg, W. D.

Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

Authors' Affiliations: ¹ Molecular Pharmacology Section; ² Clinical Pharmacology Research Core; ³ Medical Oncology Branch; ⁴ Biostatistics and Data Management Section; ⁵ The Experimental Retrovirology Section; ⁶ Dermatology Branch, National Cancer Institute, NIH, Bethesda, Maryland; ⁷ Department of Internal Medicine, University of Pisa, Italy; ⁸ Department of Clinical Pharmaceutical Sciences; and ⁹ Department of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan

Requests for reprints: William D. Figg, National Cancer Institute, Building 10/Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-402-3623; Fax: 301-402-8606; E-mail: wdfigg{at}helix.nih.gov.

Purpose: The organic anion transporter OATP1B3, encoded by SLCO1B3, is involved in the transport of steroid hormones. However, its role in testosterone uptake and clinical outcome of prostatic cancer is unknown. This study examined (a) the SLCO1B3 genotype in cancer cells as well as the uptake of testosterone by cells transfected with genetic variants of SLCO1B3; (b) the expression of OATP1B3 in normal prostate, benign prostatic hyperplasia, and prostatic cancer; and (c) the role of SLCO1B3 haplotype on clinical outcome of Caucasian patients with androgen-independent prostatic cancer.

Experimental Design: SLCO1B3 genotype was assessed in the NCI-60 panel of tumor cells by sequencing, whereas testosterone transport was analyzed in Cos-7 cells transfected with WT, 334G, and 699A SLCO1B3 variants. OATP1B3 expression in prostatic tissues was examined by fluorescence microscopy, and the relationship between SLCO1B3 haplotypes and survival was examined in patients.

Results: Cells transfected with wild-type (334T/699G) SLCO1B3, or with a vector containing either the 334G or 699A variants, actively transported testosterone, whereas its uptake was impaired in cells transfected with a gene carrying both 334G and 699A single nucleotide polymorphisms. Prostatic cancer overexpresses OATP1B3 compared with normal or benign hyperplastic tissue; patients with SLCO1B3 334GG/699AA haplotype showed longer median survival (8.5 versus 6.4 years; P = 0.020) and improved survival probability at 10 years (42% versus 23%; P < 0.023) than patients carrying TT/AA and TG/GA haplotypes.

Conclusions: The common SLCO1B3 GG/AA haplotype is associated with impaired testosterone transport and improved survival in patients with prostatic cancer.

This article has been cited by other articles:

				N. Sharifi, W. L. Dahut, and W. D. Figg The Genetics of Castration-Resistant Prostate Cancer: What Can the Germline Tell Us? Clin. Cancer Res., August 1, 2008; 14(15): 4691 - 4693. [Abstract] [Full Text] [PDF]

				T. M. Sissung, C. E. Baum, J. Deeken, D. K. Price, J. Aragon-Ching, S. M. Steinberg, W. Dahut, A. Sparreboom, and W. D. Figg ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel Clin. Cancer Res., July 15, 2008; 14(14): 4543 - 4549. [Abstract] [Full Text] [PDF]